A New Method to Model and Predict Progression Free Survival Based on Tumor Growth Dynamics

Area of Science:

• Oncology
• Clinical Trial Design
• Biostatistics

Background:

• Progression-free survival (PFS) is a key endpoint in early oncology drug development.
• Accurate PFS prediction is crucial for efficient clinical trial design and drug evaluation.
• Current models often analyze target and non-target lesion progression separately.

Purpose of the Study:

• To develop a joint statistical model for predicting PFS.
• To integrate target lesion dynamics and non-target progression risk into a single predictive framework.
• To validate the model using a platinum-resistant ovarian cancer dataset.

Main Methods:

• Utilized a pooled dataset from four treatments in platinum-resistant ovarian cancer.
• Modeled target lesion progression using Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
• Correlated non-target progression hazard with the rate of change in target lesion size.

Main Results:

• The developed joint model effectively captured target lesion tumor growth dynamics.
• The model demonstrated strong predictive performance for PFS.
• The model integrated both target and non-target lesion progression for a comprehensive PFS prediction.

Conclusions:

• A joint modeling approach can accurately predict PFS in oncology studies.
• This method enhances the prediction of clinical trial endpoints by considering multiple progression types.
• The approach holds promise for application in future cancer clinical development and research.